Gilead Sciences stock closed at USD 150.56 on the Nasdaq on September 21, 2026, marking a slight decline of 0.19 percent against a backdrop where the broader Nasdaq Composite rose 2.26 percent to 27,122.09. The company's share price finished lower than the reference index despite the general market gain. Simply Wall St reported on September 22, 2026, that Gilead maintains HIV prevention access agreements involving royalty-free lenacapavir licenses in 120 high-incidence countries and an agreement with the Pan American Health Organization. These strategic partnerships are central to the company's ongoing efforts to expand access to its key therapeutic assets globally. A dividend is scheduled to be payable on September 29, 2026, providing income to shareholders ahead of the next quarterly earnings release estimated for October 29, 2026. Market valuations cited in separate reports suggest a fair value of USD 128.38, contrasting with the current trading price of USD 150.56. The article notes that Gilead Sciences is identified by ISIN US3755581036 and operates within the biopharmaceutical sector, with specific focus on its HIV prevention portfolio and upcoming financial reporting schedule.